High Smac/DIABLO expression is associated with early local recurrence of cervical cancer
1 Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Av. San Fernando # 22, Tlalpan 14080 México City, Mexico
2 Departamento de Anatomia Patologica, Instituto Nacional de Pediatria, Insurgentes Sur # 3700, Coyoacan 04530 México City, Mexico
3 Subdireccion de Patologia, Instituto Nacional de Cancerología, Av. San Fernando # 22. Tlalpan 14080 México City. Mexico
4 Subdirección de Cirugía, Instituto Nacional de Cancerología Av. San Fernando # 22. Tlalpan 14080 México City. Mexico
BMC Cancer 2006, 6:256 doi:10.1186/1471-2407-6-256Published: 26 October 2006
In a recent pilot report, we showed that Smac/DIABLO mRNA is expressed de novo in a subset of cervical cancer patients. We have now expanded this study and analyzed Smac/DIABLO expression in the primary lesions in 109 cervical cancer patients.
We used immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections to analyze Smac/DIABLO expression in the 109 primary lesions. Seventy-eight samples corresponded to epidermoid cervical cancer and 31 to cervical adenocarcinoma. The median follow up was 46.86 months (range 10–186).
Smac/DIABLO was expressed in more adenocarcinoma samples than squamous tumours (71% vs 50%; p = 0.037). Among the pathological variables, a positive correlation was found between Smac/DIABLO immunoreactivity and microvascular density, a marker for angiogenesis (p = 0.04). Most importantly, Smac/DIABLO immunoreactivity was associated with a higher rate of local recurrence in squamous cell carcinoma (p = 0.002, log rank test). No association was found between Smac/DIABLO and survival rates.
Smac/DIABLO expression is a potential marker for local recurrence in cervical squamous cell carcinoma patients.